Ovarian Cancer
Recurrent Platinum-Resistant High-Grade Ovarian Cancer (HGOC)
Recurrent Platinum-Resistant High-Grade Ovarian Cancer (HGOC) is a challenging and aggressive condition. Many tumors develop resistance to platinum-based chemotherapy, making it harder to treat and leaving patients with limited options. Unfortunately, ovarian cancer remains one of the most serious types of cancer. According to the American Cancer Society, in 2025, it is estimated that over 21,000 women in the United States will be diagnosed with ovarian cancer, and over 12,000 will die from the disease. Nearly 70% of women with advanced ovarian cancer will experience a recurrence after their initial treatment.
Currently, treatments for recurrent platinum-resistant HGOC often include chemotherapy and immunotherapy. While these options can help, they typically have limited success in significantly improving survival rates. This highlights the need for new approaches that can better harness the immune system to target and fight cancer.
Recurrent Platinum-Resistant High-Grade Ovarian Cancer (HGOC) Clinical Trial
ResQ209: Phase 2, Open-Label Study to Evaluate the Safety and Preliminary Efficacy of Autologous M-CENK Adoptive Cell Therapy Combined with N-803 and Gemcitabine in Patients with Recurrent Platinum-Resistant High-Grade Ovarian Cancer.
This is phase 2 clinical study is exploring a potential new treatment for patients with platinum-resistant HGOC. The study is evaluating the safety and early efficacy of the combination on:
- Memory cytokine-enhanced natural killer (M-CENK) cells: A type of immune cell that may help the body fight cancer.
- N-803 (a biological agent based on IL-15): A protein that can support and activate immune cells that fight cancer.
- Gemcitabine: The standard chemotherapy drug for platinum-resistant HGOC.
Up to 20 participants will receive a combination of these therapies, with M-CENK administered through an IV, N-803 through a small injection under the skin, and gemcitabine through an IV.
How the Study Works
- Blood Collection (Apheresis): Before starting the combination treatment, participants will undergo a procedure called apheresis to collect certain blood cells. These cells will be used to create M-CENK cells.
- Treatment Cycles:
- In Cycle 1, participants will begin chemotherapy with gemcitabine.
- Starting in Cycle 2, they will also receive M-CENK and N-803, continuing the combination until M-CENK is no longer available or the cancer progresses.
Participants will be closely monitored throughout the study. After completing or stopping treatment, they will be followed every 12 weeks for up to 12 months to track their health and disease status.
This study aims to find new ways to improve outcomes for patients with recurrent HGOC, bringing hope for better options in the future.
https://clinicaltrials.gov/study/NCT06710288
- American Cancer Society. Cancer Statistics, 2025. 2025.
https://www.cancer.org/cancer/ovarian-cancer.html - Alvarez EA, et al. Immunotherapy for Ovarian Cancer: Current Approaches and Challenges. Cancer Immunol Immunother. 2023;72(5):1121-1131. https://link.springer.com/article/10.1007/s00262-023
- Xie Y, et al. Memory cytokine-enriched NK cells: A New Direction in Immunotherapy for Ovarian Cancer. J Immunol. 2022;208(3):765-772.
https://www.jimunol.org/content/208/3/765
Recent News
How Can ImmunityBio Help You?
